Company news
Soleno Therapeutics, Inc. (NASDAQ:SLNO) news
Every Soleno Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2024
Soleno Therapeutics Announces Updates to its Board of Directors
August 14, 2024
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 6, 2024
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
June 27, 2024
Soleno Therapeutics Set to Join Russell 3000® Index
June 3, 2024
Soleno Therapeutics to Participate in Upcoming Investor Conferences
May 21, 2024
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
May 21, 2024
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
May 14, 2024
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 8, 2024
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
May 1, 2024
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
May 1, 2024
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
April 29, 2024
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
April 28, 2024
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 5, 2024
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
February 21, 2024
Soleno Therapeutics to Present at Upcoming February Investor Conferences
January 31, 2024
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
January 23, 2024
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 6, 2023
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome
November 5, 2023
Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
October 3, 2023
Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
October 3, 2023
Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 1, 2023
Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
September 27, 2023
Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
September 26, 2023
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
September 25, 2023
Soleno Therapeutics to Present at the Cantor Global Healthcare Conference
September 24, 2023
Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors
August 15, 2023
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 7, 2023
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 8, 2023
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
May 2, 2023
Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days
March 27, 2023
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
March 20, 2023
Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 6, 2023
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome
January 25, 2023
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
December 18, 2022
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 8, 2022
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome
October 2, 2022
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 9, 2022
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
July 19, 2022
Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference
July 10, 2022
Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS
June 12, 2022
Soleno Therapeutics Announces Presentations at ENDO 2022
June 6, 2022
Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology
May 18, 2022
Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 16, 2022
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 9, 2022
Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome
May 1, 2022
Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering
March 31, 2022
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
March 30, 2022
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
March 28, 2022
Soleno Therapeutics Announces Proposed Underwritten Public Offering
March 27, 2022